Page last updated: 2024-12-11
stipiamide
Description
Research Excerpts
Clinical Trials
Roles
Classes
Pathways
Study Profile
Bioassays
Related Drugs
Related Conditions
Protein Interactions
Research Growth
Description
stipiamide: from Myxococcus stipitatus; effective towards multidrug-resistant cancer cells; structure given in first source [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]
Cross-References
| ID Source | ID |
|---|---|
| PubMed CID | 5467322 |
| CHEMBL ID | 1970564 |
| MeSH ID | M0189994 |
Synonyms (13)
| Synonym |
|---|
| 2,6,8,10,14-octadecahexaenamide, 13-hydroxy-n-[(1s)-2-hydroxy-1-methylethyl]- 2,10,12,14,16-pentamethyl-18-phenyl-,(2e,4e,6z,8e,10e,12r,13r,14e,16s)- |
| fenalamid a1 |
| 2,6,8,10,14-octadecahexaenamide, 13-hydroxy-n-(2-hydroxy-1-methylethyl)- 2,10,12,14,16-pentamethyl-18-phenyl-, [12r-[1(s*),2e,4e,6z,8e,10e,12r*,13r*,14e,16s*]]- |
| (-)-stipiamide |
| nsc-650717 |
| fenalamide a1 |
| phenalamide a1 |
| stipiamide |
| nsc650717 |
| 2,4,6,8,10,14-octadecahexaenamide, 13-hydroxy-n-[(1s)-2-hydroxy-1-methylethyl]-2,10,12,14,16-pentamethyl-18-phenyl-,(2e,4e,6z,8e,10e,12r,13r,14e,16s)- |
| (2e,4e,6z,8e,10e,14e)-13-hydroxy-n-(2-hydroxy-1-methyl-ethyl)-2,10,12,14,16-pentamethyl-18-phenyl-octadeca-2,4,6,8,10,14-hexaenamide |
| (2e,4e,6z,8e,10e,14e)-13-hydroxy-n-(1-hydroxypropan-2-yl)-2,10,12,14,16-pentamethyl-18-phenyloctadeca-2,4,6,8,10,14-hexaenamide |
| CHEMBL1970564 |
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]
Research
Studies (5)
| Timeframe | Studies, This Drug (%) | All Drugs % |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (20.00) | 18.2507 |
| 2000's | 3 (60.00) | 29.6817 |
| 2010's | 1 (20.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||
Study Types
| Publication Type | This drug (%) | All Drugs (%) |
|---|---|---|
| Trials | 0 (0.00%) | 5.53% |
| Reviews | 1 (20.00%) | 6.00% |
| Case Studies | 0 (0.00%) | 4.05% |
| Observational | 0 (0.00%) | 0.25% |
| Other | 4 (80.00%) | 84.16% |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||